Association between geographic access to cancer care, insurance, and receipt of chemotherapy: Geographic distribution of oncologists and travel distance

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3177-3185

  Lin, Chun Chieh ^a   Bruinooge, Suanna S ^b   Kirkwood, M Kelsey ^b   Olsen, Christine ^d   Jemal, Ahmedin ^a   Bajorin, Dean ^f   Giordano, Sharon H ^h   Goldstein, Michael ^e   Guadagnolo, B Ashleigh ^h   Kosty, Michael ⁱ   Hopkins, Shane ^j   Yu, James B ^k   Arnone, Anna ^c   Hanley, Amy ^b   Stevens, Stephanie ^c   Hershman, Dawn L ^g  

^a AMERICAN CANCER SOCIETY   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c American Society for Radiation Oncology   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ SCRIPPS CLINIC   (United States)

^j William R Bliss Cancer Center   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COLON CANCER; COLON RESECTION; COMORBIDITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICALLY UNINSURED; MEDICARE; MIDDLE AGED; ONCOLOGIST; POPULATION DENSITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; TRAVEL; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CLUSTER ANALYSIS; COLONIC NEOPLASMS; COMPARATIVE STUDY; EPIDEMIOLOGY; FACTUAL DATABASE; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; INSURANCE; MANPOWER; ODDS RATIO; ONCOLOGY; PATHOLOGY; REGISTER; RESIDENTIAL CARE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CATCHMENT AREA (HEALTH); CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; COLECTOMY; COLONIC NEOPLASMS; DATABASES, FACTUAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; LIKELIHOOD FUNCTIONS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; REGISTRIES; RISK FACTORS; TIME FACTORS; TRAVEL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84944189541     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.1558     Document Type: Article

References (45)

1. André T, Iveson T, Labianca R, et al: The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer- Trial design and current status. Curr Colorectal Cancer Rep 9: 261-269, 2013
2. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29: 1465-1471, 2011
3. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29: 3768-3774, 2011
4. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25: 2198-2204, 2007
5. Sargent D, Shi Q, Yothers G, et al: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-996, 2011
6. Baldwin LM, Dobie SA, Billingsley K, et al: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97: 1211-1220, 2005
7. Gorey KM, Haji-Jama S, Bartfay E, et al: Lack of access to chemotherapy for colon cancer: Multiplicative disadvantage of being extremely poor, inadequately insured and African American. BMC Health Serv Res 14: 133, 2014
8. Roetzheim RG, Pal N, Gonzalez EC, et al: Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 90: 1746-1754, 2000
9. Parikh AA, Robinson J, Zaydfudim VM, et al: The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. J Surg Oncol 110: 227-232, 2014
10. Lin CC, Virgo KS: Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer. J Oncol Pract 9: 27-33, 2013
11. Hendren S, Birkmeyer JD, Yin H, et al: Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum 53: 1587-1593, 2010
12. Chou S, Deily ME, Li S: Travel distance and health outcomes for scheduled surgery. Med Care 52: 250-257, 2014
13. Ahamad A: Geographic access to cancer care: A disparity and a solution. Postgrad Med J 87: 585-589, 2011
14. Probst JC, Laditka SB, Wang JY, et al: Effects of residence and race on burden of travel for care: Cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Serv Res 7: 40, 2007
15. Baldwin LM, Cai Y, Larson EH, et al: Access to cancer services for rural colorectal cancer patients. J Rural Health 24: 390-399, 2008
16. Onega T, Duell EJ, Shi X, et al: Geographic access to cancer care in the U.S. Cancer 112: 909-918, 2008
17. Chan L, Hart LG, Goodman DC: Geographic access to health care for rural Medicare beneficiaries. J Rural Health 22: 140-146, 2006
18. Ananthakrishnan AN, Hoffmann RG, Saeian K: Higher physician density is associated with lower incidence of late-stage colorectal cancer. J Gen Intern Med 25: 1164-1171, 2010
19. Roetzheim RG, Pal N, van Durme DJ, et al: Increasing supplies of dermatologists and family physicians are associated with earlier stage of melanoma detection. J Am Acad Dermatol 43: 211-218, 2000
20. Ferrante JM, Gonzalez EC, Pal N, et al: Effects of physician supply on early detection of breast cancer. J Am Board Fam Pract 13: 408-414, 2000
21. Fleisher JM, Lou JQ, Farrell M: Relationship between physician supply and breast cancer survival: A geographic approach. J Community Health 33: 179-182, 2008
22. Onega T, Duell EJ, Shi X, et al: Influence of place of residence in access to specialized cancer care for African Americans. J Rural Health 26: 12-19, 2010
23. Kirkwood MK, Bruinooge SS, Goldstein MA, et al: Enhancing the American Society of Clinical Oncology workforce information system with geographic distribution of oncologists and comparison of data sources for the number of practicing oncologists. J Oncol Pract 10: 32-38, 2014
24. Lerro CC, Robbins AS, Phillips JL, et al: Comparison of cases captured in the National Cancer Data Base with those in population-based central cancer registries. Ann Surg Oncol 20: 1759-1765, 2013
25. Fedewa SA, Etzioni R, Flanders WD, et al: Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev 19: 2437-2444, 2010
26. Centers for Medicare and Medicaid Services: Physician Compare datasets. https://data.medicare .gov/data/physician-compare
27. The Dartmouth Institute: Dartmouth Atlas of Health Care. http://www.dartmouthatlas.org/data/region/
28. Massarweh NN, Chiang YJ, Xing Y, et al: Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol 32: 942-948, 2014
29. Wang EH, Mougalian SS, Soulos PR, et al: Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: A National Cancer Data Base analysis. Int J Radiat Oncol Biol Phys 90: 993-1000, 2014
30. Charlson ME, Pompei P, Ales KL, et al: A new method for classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383, 1987
31. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619, 1992
32. Romano PS, Roos LL, Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46: 1075-1079, 1993
33. Klabunde CN, Harlan LC, Warren JL: Data sources for measuring comorbidity: A comparison of hospital records and Medicare claims for cancer patients. Med Care 44: 921-928, 2006
34. Klabunde CN, Legler JM, Warren JL, et al: A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17: 584-590, 2007
35. Gruca TS, Nam I, Tracy R: Trends in medical oncology outreach clinics in rural areas. J Oncol Pract 10: e313-e320, 2014
36. Guidry JJ, Aday LA, Zhang D, et al: Transportation as a barrier to cancer treatment. Cancer Pract 5: 361-366, 1997
37. Scoggins JF, Fedorenko CR, Donahue SM, et al: Is distance to provider a barrier to care for Medicaid patients with breast, colorectal, or lung cancer? J Rural Health 28: 54-62, 2012
38. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004
39. Cheeseman SL, Joel SP, Chester JD, et al: A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87: 393-399, 2002
40. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer: Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11: 1477-1483, 2000
41. Ko NY, Darnell JS, Calhoun E, et al: Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. J Clin Oncol 32: 2758-2764, 2014
42. Rieber GM, Benzie D, McMahon S: Why patients bypass rural health care centers. Minn Med 79: 46-50, 1996
43. Meyerhardt JA, Catalano PJ, Schrag D, et al: Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139: 649-657, 2003
44. Lund JL, Stürmer T, Sanoff HK, et al: Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer 119: 2038-2047, 2013
45. Sanoff HK, Carpenter WR, Stürmer T, et al: Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30: 2624-2634, 2012